Corresponding Author: Daniel E. Spratt, MD, Department of Radiation Oncology, University of Michigan, 1500 E Medical Center Dr; Ann Arbor, MI 48109 (sprattend@med.umich.edu).

Published Online: October 31, 2019. doi:10.1001/jamaoncol.2019.4509

Conflict of Interest Disclosures: Dr Spratt reports personal fees from Janssen outside the submitted work. No other disclosures were reported.


Failure to Disclose Potential Conflict of Interest—Letter of Explanation

To the Editor We write to report our failure to disclose a potential conflict of interest in our disclosure statements published in the article, “Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins,” that was published in JAMA Oncology online first on July 12, 2018, and with the October 2018 issue.1 This validation study found that a risk prediction model that included 4 protein biomarkers that was developed in a cohort of US individuals at high risk of lung cancer outperformed a model based on smoking history alone when validated using prediagnostic samples from 2 European cohorts.

In February of 2018, a patent was filed for “Methods for the Detection and Treatment of Lung Cancer” based on the data included in this article and with the 3 of us named as inventors. We did not include this information in our disclosures to the journal because we did not appreciate that filing a patent represents a financial conflict of interest. It was an oversight on our part that “planned, pending, or issued patents,” as defined in the journal’s conflict of interest disclosure policy and authorship forms, should have been disclosed. We apologize for this omission and have requested that the article be corrected to include the following disclosure: “Drs Taguchi, Feng, and Hanash report the filing of a patent, Methods for the Detection and Treatment of Lung Cancer (WO2018148600), based on the data included in this article.”

CORRECTION

Failure to Disclose a Potential Conflict of Interest: In the Original Investigation titled “Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins,” published in JAMA Oncology online first on July 12, 2018, and with the October 2018 issue, a potential conflict of interest was not reported. Three of the authors, Drs Taguchi, Feng, and Hanash, had filed a patent, Methods for the Detection and Treatment of Lung Cancer (WO2018148600), based on the data included in this article. This article was corrected online. This article was also corrected on September 13, 2018, for an error in an author surname.


Error in the Figure: In the Research Letter titled “Association Between Aspirin Use and Biliary Tract Cancer Survival,” published online October 17, 2019, there was an error in the Figure. Numbers at risk data for all cancer sites were repeated under each panel. This article was corrected online.


Error in Figure 2D: In the Original Investigation titled “Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer,” published online October 17, 2019, a correction was made to Figure 2D to fix the label “Negative-positive,” which had been written as “Positive-negative.” This article was corrected online.